ALK Abello meets expectations in first half of 2012

ALK Abello has published its six-month interim financial report for 2012, during which it delivered a performance that was in line with its forecasts for the year.

Revenue for the period came to 1.12 billion Danish kroner (117.66 million pounds), with vaccine sales growing by 3.3 percent year-on-year, while allergy immunotherapy tablet sales advanced by 19 percent.

Net profit levels grew to 168 million kroner, compared to 140 million kroner in the first half of 2011, with the company also progressing with the rollout of its Jext adrenaline pen.

Other highlights of the period include advancement of the clinical development of the dust mite-induced hay fever and asthma treatment Mitizax in the US and Japan, as well as a new ragweed allergy tablet being developed alongside Merck Sharp and Dohme.

Additionally, the company made various new staff appointments, with Soren Daniel Niegel becoming executive vice-president for international sales and marketing earlier this month.

For the full year, ALK Abello expects growth in vaccines sales of between three and five percent and a revenue total of up to 2.4 billion kroner, as well as a record level of research and development activity.